- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04445298
Skin Barrier Assessment in Pregnancy and at Birth
September 8, 2020 updated by: National Jewish Health
This is a prospective birth cohort study assessing the role of maternal and environmental factors on the development of allergic diseases in children.
Pregnant mothers will be enrolled and we will examine her skin barrier with skin tape strips (STS) and transepidermal water loss (TEWL), along with blood work.
We will then follow her offspring and perform similar testing, along with detailed questionnaires inquiring about exposures such as use of detergents and soaps, sunlight exposure, and pollution exposure.
When the infant is around 12 months old, we will contact the family via telephone to see if the child developed any allergic conditions within their first year of life, such as eczema, food allergy, or wheezing.
A final questionnaire will be performed.
Study Overview
Status
Unknown
Study Type
Observational
Enrollment (Anticipated)
160
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Jessica W Hui, MD
- Phone Number: 3033981245
- Email: huij@njhealth.org
Study Locations
-
-
Colorado
-
Denver, Colorado, United States, 80206
- Recruiting
- National Jewish Health
-
Contact:
- Jessica Hui, MD
- Email: huij@njhealth.org
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
1 second to 55 years (Child, Adult)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Sampling Method
Non-Probability Sample
Study Population
We will enroll up to 40 pregnant mothers who are expected to deliver in the fall and winter, along with up to 40 pregnant mothers who are expected to deliver in the spring and summer.
The infants will then be enrolled and followed in the study.
Description
Inclusion Criteria:
Inclusion criteria of the pregnant women:
• Pregnant women at any stage of a singleton pregnancy.
Inclusion criteria of the infant:
• Infant is the offspring of a woman enrolled in the study.
Exclusion Criteria:
Exclusion criteria of all subjects:
- Use of systemic immunosuppressive drugs including oral steroids within 30 days of skin barrier assessment
- Has received total body phototherapy (e.g., ultraviolet light B [UVB], psoralen plus ultraviolet light A [PUVA], tanning beds [>1 visit per week]) within 30 days of skin barrier assessment
- Use of topical corticosteroids, topical immunomodulatory agents, or topical antibiotics on the extremity being evaluated within 7 days of skin barrier assessment
- Use of systemic antibiotics, antiparasitics, antivirals, or antifungals within 7 days, or antihistamines within 5 days of skin barrier assessment
- Has taken a bleach bath within 7 days of skin barrier assessment
- Use of emollients on the extremity being evaluated within 24 hours of skin barrier assessment
- Has taken a bath or shower on the day of the skin barrier assessment
Exclusion criteria of the pregnant women:
- Pregnant women with high risk pregnancies.
- Pregnancy is from an egg donation.
- Pregnant women pregnant with more than one fetus.
- Pregnant women with psychiatric and developmental co-morbidities that would render them unable to provide informed consent or perform study-related procedures.
- AIDS and HIV infection.
- A fetus with chromosomal or congenital abnormalities, a heritable hematological disorder like thalassemia or sickle cell disease in the mother.
Exclusion criteria of the infant:
- Infant is delivered earlier than 34 weeks gestation.
- Infant is born with a significant birth defect or medical condition where enrollment in this study is not in the infant's best interest.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Pregnant women with expected delivery in the fall or winter
We will enroll up to 40 women who are expected to deliver in the fall (September, October, November) and winter (December, January, February).
We will then follow their infant offspring.
|
We will assess the skin with transepidermal water loss (TEWL) by using a condenser-chamber system placed lightly on the skin.
This will be performed at baseline, then after every 4 skin tape strips.
Other Names:
Adhesive skin sampling discs will be pressed against the skin in a hairless location followed by lifting it free of the skin.
The discs will be evaluated for lipid content, protein, and filaggrin byproducts in the collected skin sample.
Other Names:
We will draw blood to look at the vitamin D, total immunoglobulin E (IgE), and the filaggrin gene which is important in maintaining the skin barrier.
Skin swab from the superficial skin will be collected to be assessed in the laboratory via PCR for the presence of staphylococcus aureus.
Other Names:
|
Pregnant women with expected delivery in the spring or summer
We will enroll up to 40 women who are expected to deliver in the spring (March, April, May) and summer (June, July, August).
We will then follow their infant offspring.
|
We will assess the skin with transepidermal water loss (TEWL) by using a condenser-chamber system placed lightly on the skin.
This will be performed at baseline, then after every 4 skin tape strips.
Other Names:
Adhesive skin sampling discs will be pressed against the skin in a hairless location followed by lifting it free of the skin.
The discs will be evaluated for lipid content, protein, and filaggrin byproducts in the collected skin sample.
Other Names:
We will draw blood to look at the vitamin D, total immunoglobulin E (IgE), and the filaggrin gene which is important in maintaining the skin barrier.
Skin swab from the superficial skin will be collected to be assessed in the laboratory via PCR for the presence of staphylococcus aureus.
Other Names:
|
Infants born in the fall or winter
The infants born to the enrolled mothers will be followed.
These are infants born in the fall (September, October, November) or winter (December, January, February).
|
We will assess the skin with transepidermal water loss (TEWL) by using a condenser-chamber system placed lightly on the skin.
This will be performed at baseline, then after every 4 skin tape strips.
Other Names:
Adhesive skin sampling discs will be pressed against the skin in a hairless location followed by lifting it free of the skin.
The discs will be evaluated for lipid content, protein, and filaggrin byproducts in the collected skin sample.
Other Names:
We will draw blood to look at the vitamin D, total immunoglobulin E (IgE), and the filaggrin gene which is important in maintaining the skin barrier.
Skin swab from the superficial skin will be collected to be assessed in the laboratory via PCR for the presence of staphylococcus aureus.
Other Names:
|
Infants born in the spring or summer
The infants born to the enrolled mothers will be followed.
These are infants born in the spring (March, April, May) or summer (June, July, August).
|
We will assess the skin with transepidermal water loss (TEWL) by using a condenser-chamber system placed lightly on the skin.
This will be performed at baseline, then after every 4 skin tape strips.
Other Names:
Adhesive skin sampling discs will be pressed against the skin in a hairless location followed by lifting it free of the skin.
The discs will be evaluated for lipid content, protein, and filaggrin byproducts in the collected skin sample.
Other Names:
We will draw blood to look at the vitamin D, total immunoglobulin E (IgE), and the filaggrin gene which is important in maintaining the skin barrier.
Skin swab from the superficial skin will be collected to be assessed in the laboratory via PCR for the presence of staphylococcus aureus.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Skin barrier assessment with transepidermal water loss (TEWL) will be done in every infant.
Time Frame: 1 year
|
TEWL will be performed in all infants to compare skin barrier assessments between infants born in the fall and winter with those born in the spring and summer.
We hypothesize greater skin barrier dysfunction in those born in the fall and winter.
|
1 year
|
Skin barrier assessment with skin tape stripping (STS) will be done in every infant.
Time Frame: 1 year
|
STS will be performed in all infants to compare skin barrier assessments between infants born in the fall and winter with those born in the spring and summer.
We hypothesize greater skin barrier dysfunction in those born in the fall and winter.
|
1 year
|
Skin barrier assessment with skin swabs for staphylococcus aureus colonization will be done in every infant.
Time Frame: 1 year
|
Skin swabs for staphylococcus aureus colonization will be performed in all infants to compare skin barrier assessments between infants born in the fall and winter with those born in the spring and summer.
We hypothesize greater staphylococcus aureus colonization in those born in the fall and winter.
|
1 year
|
Skin barrier assessment with TEWL will be performed in every pregnant female and compared to her infant offspring, as well as between other pregnant females giving birth in other seasons.
Time Frame: 1 year
|
We will compare the mother's skin barrier with the infant skin barrier to see if there is an association with the mother's skin barrier during pregnancy.
We will perform TEWL to assess the degree of water loss before, during, and after skin tape stripping.
|
1 year
|
Skin barrier assessment with STS will be performed in every pregnant female and compared to her infant offspring, as well as between other pregnant females giving birth in other seasons.
Time Frame: 1 year
|
We will compare the mother's skin barrier with the infant skin barrier to see if there is an association with the mother's skin barrier during pregnancy.
We will perform STS to determine the skin breakdown products.
|
1 year
|
Skin barrier assessment with skin swabs for staphylococcus aureus colonization will be performed in every pregnant female and compared to her infant offspring, as well as between other pregnant females giving birth in other seasons.
Time Frame: 1 year
|
We will compare the mother's skin barrier with the infant skin barrier to see if there is an association with the mother's skin barrier during pregnancy.
We will perform skin swabs for staphylococcus aureus colonization to determine the presence of colonization.
|
1 year
|
Skin barrier assessment with filaggrin gene mutation status will be determined in everyone enrolled, and we will look for the filaggrin gene mutation in both the mother and infant.
Time Frame: 1 year
|
The filaggrin gene is important for skin health, and we will assess for common filaggrin gene mutations in everyone enrolled in this study via a blood draw in the mother's and cord blood in the infants.
|
1 year
|
Vitamin D levels will be obtained and compared between individuals enrolled in this study.
Time Frame: 1 year
|
Vitamin D levels will be obtained by blood draw in the pregnant mother's and cord blood in the infants.
We will compare the values according to season of birth, as we hypothesize that the infants born in the fall and winter, along with their mothers, will have a lower vitamin D level.
|
1 year
|
Questionnaires regarding exposures will be compared with the skin barrier measurements to understand exposures that lead to increased skin barrier dysfunction.
Time Frame: 1 year
|
Questionnaires will be administered to capture exposures during pregnancy, such as detergents, soaps, medications, and sunlight exposure.
The answers will be compared with the results of the skin barrier assessment in both pregnant women and their infants to understand which exposures lead to skin barrier dysfunction.
|
1 year
|
Questionnaires and a follow up telephone call will allow us to see if infants born in the fall and winter have a higher incidence of allergy development.
Time Frame: 1 year
|
Questionnaires and follow up telephone calls when the infant is 12 months old will determine which infants develop allergic conditions, such as atopic dermatitis, food allergy, and wheezing.
We will compare the infants born in the fall and winter with those born in the spring and summer to see whether the infants born in the fall and winter have increased risk of developing allergy.
|
1 year
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Donald Leung, MD PhD, National Jewish Health
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
August 3, 2020
Primary Completion (Anticipated)
July 1, 2022
Study Completion (Anticipated)
July 1, 2022
Study Registration Dates
First Submitted
April 29, 2020
First Submitted That Met QC Criteria
June 22, 2020
First Posted (Actual)
June 24, 2020
Study Record Updates
Last Update Posted (Actual)
September 10, 2020
Last Update Submitted That Met QC Criteria
September 8, 2020
Last Verified
September 1, 2020
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- HS3513
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
UNDECIDED
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Allergy
-
University of RochesterNational Institute of Allergy and Infectious Diseases (NIAID)Not yet recruitingEgg Allergy | Food Allergy Peanut | Food Allergy in Infants | Allergy and Immunology | Peanut and Nut AllergyUnited States
-
Hong Kong Sanatorium & HospitalChinese University of Hong KongTerminatedAllergy to Fish | Allergy to Shrimp | Allergy to CrabHong Kong
-
King's College LondonGuy's and St Thomas' NHS Foundation TrustUnknownEgg Allergy | Food Allergy | Food Allergy in Children | Milk Allergy | Food Allergy in Infants | Nut Allergy | Food Allergen SensitisationUnited Kingdom
-
Abionic SAJohns Hopkins University; NAMSAWithdrawnAllergy | Allergic Asthma | Allergy to Cats | Allergy to House Dust | Allergy Cockroach | Allergy to Dog Dander (Finding) | Allergy MoldUnited States
-
Peking University Third HospitalCancer Institute and Hospital, Chinese Academy of Medical Sciences; Beijing... and other collaboratorsRecruitingCow Milk Allergy | Food Allergy in ChildrenChina
-
King's College LondonKing's College Hospital NHS Trust; University College London Hospitals; Cambridge... and other collaboratorsRecruitingEgg Allergy | Food Allergy | Food Allergy in Children | Milk Allergy | Food Allergy in Infants | Nut Allergy | Food Allergen SensitisationUnited Kingdom
-
Chinese University of Hong KongRecruiting
-
Martini Hospital GroningenRecruitingCow Milk Allergy | Food AllergyNetherlands
-
Sayantani B. SindherNational Institute of Allergy and Infectious Diseases (NIAID)TerminatedAllergy;Food | Allergy to Shrimp | Allergy to Cashew Nut (Disorder)United States
-
University GhentActive, not recruitingCow Milk Allergy | Food AllergyBelgium
Clinical Trials on Transepidermal water loss
-
Pierre Fabre Dermo CosmetiqueCompleted
-
Pierre Fabre Dermo CosmetiqueUnknownHealthy | Rosacea | Seborrheic Dermatitis | Atopic Dermatitis | Psoriasis Vulgaris | AcneFrance
-
National Jewish HealthWithdrawnEczema | Atopic Dermatitis | Food AllergyUnited States
-
University of MichiganThe Gerber FoundationRecruiting
-
NAOS Argentina S.A.RecruitingAtopic Dermatitis | Eczema, AtopicArgentina, Singapore
-
University of California, DavisCompletedSmoking | Aging | Atopic Dermatitis | AcneUnited States
-
University of VermontUniversity of Vermont Medical CenterCompletedBreast Cancer | Overweight | PostmenopausalUnited States
-
University of PittsburghCompleted
-
VA Office of Research and DevelopmentTerminatedOverweight | Obstructive Sleep ApneaUnited States
-
University of Alabama at BirminghamNational Cancer Institute (NCI)Completed